Brain Scientific’s disposable EEG cap can be applied by any clinical staff member within 5 minutes.
Brain Scientific recently announced that a child-size version of its next-generation disposable electroencephalogram (EEG) cap, NeuroCap, will soon become available to the pediatric market.
The pre-gelled, hospital grade NeuroCap features 19 active EEG channels and 22 electrodes and takes 5 minutes to apply to the head by any clinical staff member. The use of the NeuroCap aims to simplify conducting pediatric EEGs, as clinicians will be able to bypass measuring and marking the patient’s head, gelling electrodes, and the sanitizing that is required with a non-disposable unit, making the rapid-result device appropriate for both emergency and clinic settings.1.2
“The NeuroCap headset is ready to be utilized in facilities across the country, and now with the pediatric size cap we can reach even more patients who need access to sanitary, convenient and prompt EEG testing,” said Irina Nazarova, Marketing Director, Brain Scientific, in a statement. “We are thrilled to roll out a needed solution within pediatrics that is easily and affordably implemented in healthcare facilities for clinicians to use with precision and confidence.”
Brain Scientific noted it seeks to meet the needs of EEG testing in children that stem from various symptoms including seizures, sleep troubles, brain infections, and neurological disorders such as epilepsy and ADHD. Pediatric epilepsy has become among the most common neurological disorders seen in children and rates of ADHD diagnoses have increased by 42% in the US over the past decade.3,4
Nazaroza commented on the next generation NeuroCap in another statement, saying “this next generation NeuroCap is a hospital-grade disposable EEG headset that has 22 electrodes and 19 active EEG channels. We use Velcro for better adhesion in the new cap. The device is designed for broader use—in addition to intensive care units and ERs.”
According to Brain Scientific, estimates suggest that approximately 5 million patients in US emergency departments and ICUs are subject to seizures and could benefit from routine EEG tests, and that 26 people in the US will be diagnosed with epilepsy at some point in their life, while only 254 of 6210 US hospitals are Level 4 epilepsy centers with 24/7 EEG services. To this end, the pediatric NeuroCap is expected to be available to clinicians in the US in early 2021.
Brain Scientific also submitted a premarket 510(k) application for FDA approval in October 2020 in an attempt to meet the neurological needs presented by the COVID-19 pandemic. The disposable nature of the device also accommodates stricter sanitization protocols amidst the pandemic. Around 80% of patients with COVID-19 exhibit neurological symptoms that could require EEG testing.
NeurologyLive has talked to many experts about neurological symptoms seen in COVID-19 patients. One such interview on secondary headache disorders associated with COVID-19 infection, such as cerebral venous thrombosis, cervical artery dissection, and post-irreversible encephalopathy, can be found by clicking here.